Pemetrexed Followed by Docetaxel or in Reverse Sequence
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Both pemetrexed and docetaxel have been reported to have similar activity against non-small
cell lung cancer (NSCLC) who failed previous chemotherapy in a large randomized phase III
study. However, no study showed different toxicity and efficacy profiles within individual
patients. Present phase II randomized clinical trial is designed to answer these questions,
with addition of information about whether or not sequential therapy can prolong disease-free
and overall survival.